Citation Impact
Citing Papers
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
2008 Standout
CD4+ T Cell Depletion during all Stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract
2004 Standout
CD4+ Count–Guided Interruption of Antiretroviral Treatment
2006 Standout
Nanotechnology advances in pathogen- and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control
2021
Novel therapeutic strategies targeting HIV integrase
2012
Improved metagenomic analysis with Kraken 2
2019 Standout
Heparin-Protein Interactions
2002 Standout
Annexin V interactions with collagen
1997
Transmission of HIV-1 drug resistance
2004
Hepatitis B Virus Infection — Natural History and Clinical Consequences
2004 Standout
QM/MM Methods for Biomolecular Systems
2009 Standout
HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo
2008
Modelling the Impact of Antiretroviral Use in Resource-Poor Settings
2006
Barriers to HAART Adherence Among Human Immunodeficiency Virus–Infected Adolescents
2003
Incidence and impact of resistance against approved antiretroviral drugs
2000
Allosteric Inhibitor Development Targeting HIV‐1 Integrase
2011
Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies
2016 StandoutNobel
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
2007
HIV preferentially infects HIV-specific CD4+ T cells
2002 Nature
Child and adolescent mental health worldwide: evidence for action
2011 Standout
HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
2011
Early Immunologic Failure is Associated With Early Mortality Among Advanced HIV–Infected Adults Initiating Antiretroviral Therapy With Active Tuberculosis
2013 StandoutNobel
New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays
2010 Standout
Microbial translocation is a cause of systemic immune activation in chronic HIV infection
2006 Standout
Solution Conformation and Dynamics of the HIV-1 Integrase Core Domain
2010
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model
2008 Standout
Viral Population Estimation Using Pyrosequencing
2008
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
2021 StandoutNobel
Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection
2003
Lipodystrophy Syndromes
2008
Structural Basis for the Resilience of Efavirenz (DMP-266) to Drug Resistance Mutations in HIV-1 Reverse Transcriptase
2000
Newly approved integrase inhibitors for clinical treatment of AIDS
2014
Incidence of Resistance in a Double‐Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine
2004
Organ and species specificity of hepatitis B virus (HBV) infection: a review of literature with a special reference to preferential attachment of HBV to human hepatocytes
1997
Characterization of Liver T–Cell Receptor γδ+ T Cells Obtained From Individuals Chronically Infected With Hepatitis C Virus (Hcv): Evidence for These T Cells Playing A Role in the Liver Pathology Associated With Hcv Infections
2001 StandoutNobel
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
The growing impact of click chemistry on drug discovery
2003 StandoutNobel
Optimization of methods to assess human mucosal T-cell responses to HIV infection
2003
Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection.
1996 StandoutNobel
A Prospective, Randomized Trial of Structured Treatment Interruption for Patients with Chronic HIV Type 1 Infection
2005
Resistance to Protease Inhibitors
2001
Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation
2010 Standout
Virosomes: evolution of the liposome as a targeted drug delivery system
2000
Dynamics and functions of lipid droplets
2018 Standout
Myocarditis
2011 Standout
The end of AIDS: HIV infection as a chronic disease
2013 Standout
Structured Treatment Interruptions for the Management of HIV Infection
2001
Pharmacokinetics, Safety, and Efficacy of Tipranavir Boosted With Ritonavir Alone or in Combination With Other Boosted Protease Inhibitors as Part of Optimized Combination Antiretroviral Therapy in Highly Treatment-Experienced Patients (BI Study 1182.51)
2008
The interaction of HIV with dendritic cells: outcomes and pathways
2007 StandoutNobel
HIV Drug Resistance
2004
Hepatitis B Virus Transgenic Mice: Models of Viral Immunobiology and Pathogenesis
1996
Tipranavir: a novel protease inhibitor for HIV therapy
2009
Receptor-mediated entry of hepatitis B virus particles into liver cells
1997
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
2020 Standout
Antiretroviral Drug Resistance Testing in Adult HIV‐1 Infection: 2008 Recommendations of an International AIDS Society–USA Panel
2008
Involvement of annexin V in the entry of influenza viruses and role of phospholipids in infection
1996
Antiretroviral Treatment for Adult HIV Infection in 2002
2002
Regulation of type I interferon responses
2013 Standout
The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance
2001
CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial
2006
Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study
2007
A Quantum Mechanics/Molecular Mechanics Study of the Protein–Ligand Interaction for Inhibitors of HIV‐1 Integrase
2007
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
2009 Standout
Immunological recovery and antiretroviral therapy in HIV-1 infection
2006
Inhibition of HIV replication: A powerful antiviral strategy by IFN-β gene delivery in CD4+ cells
2007 StandoutNobel
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection
2005 StandoutNature
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Promoting child and adolescent mental health in the context of the HIV/AIDS pandemic with a focus on sub‐Saharan Africa
2008
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells
2003 Standout
Hybrid Quantum Mechanical/Molecular Mechanical Molecular Dynamics Simulations of HIV-1 Integrase/Inhibitor Complexes
2007
Steady‐State Pharmacokinetics of Emtricitabine and Tenofovir Disoproxil Fumarate Administered Alone and in Combination in Healthy Volunteers
2007
HIV-1 Neutralization Profile and Plant-Based Recombinant Expression of Actinohivin, an Env Glycan-Specific Lectin Devoid of T-Cell Mitogenic Activity
2010 StandoutNobel
Stem cell-derived polarized hepatocytes
2020 StandoutNobel
HIV-1 Drug Resistance Profiles in Children and Adults With Viral Load of <50 Copies/mL Receiving Combination Therapy
2001
Antiretroviral Therapy in Adults
2000
Adherence to Medication
2005 Standout
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
2013 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Persistence of Wild-Type Virus and Lack of Temporal Structure in the Latent Reservoir for Human Immunodeficiency Virus Type 1 in Pediatric Patients with Extensive Antiretroviral Exposure
2002
Characterization and structural analysis of HIV-1 integrase conservation.
2009
HIV infection and the gastrointestinal tract
2005
HIV Treatment Failure: Testing for HIV Resistance in Clinical Practice
1998 Science
Clonal B cells in patients with hepatitis C virus–associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset
2011 StandoutNobel
Detection of Human Immunodeficiency Virus (HIV) Type 1 M184V and K103N Minority Variants in Patients with Primary HIV Infection
2009
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
The challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART.
2009
Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles
1997 StandoutNobel
Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications
2007
An N-Terminal Amphipathic Helix in Hepatitis C Virus (HCV) NS4B Mediates Membrane Association, Correct Localization of Replication Complex Proteins, and HCV RNA Replication
2004 StandoutNobel
Carbamoyl Pyridone HIV-1 Integrase Inhibitors. 2. Bi- and Tricyclic Derivatives Result in Superior Antiviral and Pharmacokinetic Profiles
2013
Decreased Survival of B Cells of HIV-viremic Patients Mediated by Altered Expression of Receptors of the TNF Superfamily
2004
Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection
2000
Carbamoyl Pyridone HIV-1 Integrase Inhibitors. 1. Molecular Design and Establishment of an Advanced Two-Metal Binding Pharmacophore
2012
A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1
2000
IMMUNOBIOLOGY AND PATHOGENESIS OF VIRAL HEPATITIS
2006
Imbroglios of Viral Taxonomy: Genetic Exchange and Failings of Phenetic Approaches
2002
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
2018
Interventions for enhancing medication adherence
2014 Standout
Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors
2011
High Levels of Viral Replication Contrast with Only Transient Changes in CD4+and CD8+Cell Numbers during the Early Phase of Experimental Infection with Simian Immunodeficiency Virus SIVmnd-1 inMandrillus sphinx
2002 StandoutNobel
Annexins: From Structure to Function
2002 Standout
Antiretroviral Therapy in Macrophages: Implication for HIV Eradication
2009
Mature Dendritic Cells Infected with Canarypox Virus Elicit Strong Anti-Human Immunodeficiency Virus CD8+and CD4+T-Cell Responses from Chronically Infected Individuals
2001 StandoutNobel
Influence of Alternative Thresholds for Initiating HIV Treatment on Quality-Adjusted Life Expectancy: A Decision Model
2008
Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
2014 StandoutNobel
Virtual Screening, Identification, and Biochemical Characterization of Novel Inhibitors of the Reverse Transcriptase of Human Immunodeficiency Virus Type-1
2008
Determination of the Structures of Symmetric Protein Oligomers from NMR Chemical Shifts and Residual Dipolar Couplings
2011 StandoutNobel
Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors
2004 StandoutNobel
The Engagement of Activating FcγRs Inhibits Primate Lentivirus Replication in Human Macrophages
2006 StandoutNobel
Vinylogous Ureas as a Novel Class of Inhibitors of Reverse Transcriptase-Associated Ribonuclease H Activity
2008
Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8 + T cells
2010 StandoutNobel
Association of Saquinavir Plasma Concentrations with Side Effects but Not with Antiretroviral Outcome in Patients Infected with Protease Inhibitor-Susceptible Human Immunodeficiency Virus Type 1
2007
Indispensable Role for TNF-α and IFN-γ at the Effector Phase of Liver Injury Mediated by Th1 Cells Specific to Hepatitis B Virus Surface Antigen
2000
Quinolone 3-Carboxylic Acid Pharmacophore: Design of Second Generation HIV-1 Integrase Inhibitors
2008
Nanobodies: Natural Single-Domain Antibodies
2013 Standout
Resistance to Protease Inhibitors
2001
Crystal Structures of Zidovudine- or Lamivudine-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptases Containing Mutations at Codons 41, 184, and 215
2002
Works of Kurt Hertogs being referenced
Indolopyridones Inhibit Human Immunodeficiency Virus Reverse Transcriptase with a Novel Mechanism of Action
2006
Long‐Cycle Structured Intermittent versus Continuous Highly Active Antiretroviral Therapy for the Treatment of Chronic Infection with Human Immunodeficiency Virus: Effects on Drug Toxicity and on Immunologic and Virologic Parameters
2003
Hepatitus B virus: specific binding and internalization of small HBsAg by human hepatocytes
1995
High Prevalence of Genotypic and Phenotypic HIV-1 Drug-Resistant Strains Among Patients Receiving Antiretroviral Therapy in Abidjan, Côte d'Ivoire
2001
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples
2000
Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV drug access initiative – Uganda
2003
A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
2002
Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen
2002
Dual Resistance to Zidovudine and Lamivudine in Patients Treated with Zidovudine‐Lamivudine Combination Therapy: Association with Therapy Failure
1998
Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor
2011
ANTIVIRAL ACTIVITY OF TENOFOVIR (PMPA) AGAINST NUCLEOSIDE-RESISTANT CLINICAL HIV SAMPLES
2001
Primary Genotypic and Phenotypic HIV-1 Drug Resistance in Recent Seroconverters in Madrid
2001
Transfection of A Rat Hepatoma Cell Line With A Construct Expressing Human Liver Annexin V Confers Susceptibility to Hepatitis B Virus Infection
1999
A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional Nanobodies
2012
Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS–Drug Access Initiative in Abidjan, Côte dʼIvoire
2003
Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure
2000
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
2000
Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration
2003
CRF06-cpx: A New Circulating Recombinant Form of HIV-1 in West Africa Involving Subtypes A, G, K, and J
2002
Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes
2009
Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles
2010
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples
2000
Low Prevalence of Antiretroviral Drug Resistance among HIV-1 Seroconverters in London, 1984–1991
2002
The M184 V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors
1998
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
1999
Endonexin II, Present on Human Liver Plasma Membranes, Is a Specific Binding Protein of Small Hepatitis B Virus (HBV) Envelope Protein
1993
Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel
2000
Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance
2006
Resistance to Antiretroviral Therapy Among Patients in Uganda
2001
Binding Kinetics of Darunavir to Human Immunodeficiency Virus Type 1 Protease Explain the Potent Antiviral Activity and High Genetic Barrier
2007
Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors
2008
Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters
2001
Despite High Concordance, Distinct Mutational and Phenotypic Drug Resistance Profiles in Human Immunodeficiency Virus Type 1 RNA Are Observed in Gastrointestinal Mucosal Biopsy Specimens and Peripheral Blood Mononuclear Cells Compared with Plasma
2001
Spontaneous development of anti-hepatitis B virus envelope (anti-idiotypic) antibodies in animals immunized with human liver endonexin II or with the F(ab')2 fragment of anti-human liver endonexin II immunoglobulin G: evidence for a receptor-ligand-like relationship between small hepatitis B surface antigen and endonexin II
1994
Design and Optimization of Tricyclic Phtalimide Analogues as Novel Inhibitors of HIV-1 Integrase
2004
A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs
1998
HIV Drug Susceptibility and Treatment Response to Mega-Haart Regimen in Patients from the Frankfurt HIV Cohort
2000
Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy
2001
Correlation between Viral Resistance to Zidovudine and Resistance at the Reverse Transcriptase Level for a Panel of Human Immunodeficiency Virus Type 1 Mutants
2001
A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance
1999
A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184V
2000
Patterns of Resistance and Cross-Resistance to Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors in Patients Treated with the Nonnucleoside Reverse Transcriptase Inhibitor Loviride
1998